MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas
Constitutional MGMT promoter methylation in normal tissue is not associated with an increased risk of developing colon cancer, glioblastoma, or B-cell lymphoma.
Authors
- Rowan T. Chlebowski (ORCID: https://orcid.org/0000-0002-4212-6184)
- Oleksii Nikolaienko (ORCID: https://orcid.org/0000-0002-5910-4934)
- Su Yon Jung (ORCID: https://orcid.org/0000-0002-0513-1830)
- Per Eystein Lønning (ORCID: https://orcid.org/0000-0002-8890-6303)
- Garnet L. Anderson (ORCID: https://orcid.org/0000-0001-5087-7837)
- Holly Ruth Harris (ORCID: https://orcid.org/0000-0002-2572-6727)
- Stian Knappskog (ORCID: https://orcid.org/0000-0002-4153-1655)
Institutions
- University of California, Los Angeles (US)
- Haukeland University Hospital (NO)
- Fred Hutch Cancer Center (US)
- University of Bergen (NO)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1186/s13148-025-01835-x
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Brigham and Women's Hospital
- Ohio State University
- Wake Forest University
- University of Pittsburgh
- Kreftforeningen
- University of Nevada, Reno
- MedStar Health Research Institute
- Norges Forskningsråd
- University at Buffalo
- National Heart, Lung, and Blood Institute